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 Abstract    
Goal: The aim of the study was to estimate potential associations of vitamin D concentration with metabolic and 
hormonal indices in women with polycystic ovary syndrome (PCOS) presenting abdominal and gynoidal type of 
obesity. 
Material and methods: Twenty-six women with PCOS (19-49 years old, BMI: 26.8-53.8 kg/m2), presenting pre-
dominantly abdominal and gynoidal type of obesity, were recruited. Anthropometric measures, body composition 
using dual-energy absorptiometry, fasting serum 25-hydroxyvitamin D, leptin, glucose, insulin, homeostatic model of 
assessment (HOMA), lipids, androgens and sex hormone-binding globulin (SHGB) were estimated. 
Results: Vitamin D insufficiency was found in 2, and deficiency or deep deficiency in 12 patients. Levels of vitamin 
D were lower in obese than non-obese women, and in patients with abdominal as compared to gynoidal obesity 
(9.60±3.7 vs. 16.02±3.3 ng/mL, p<0.04). In obese women, vitamin D correlated negatively with all, except for gy-
noidal fat, measures of obesity, fasting glucose levels, and HOMA. No correlations with androgens were found. In 
women with abdominal obesity, vitamin D correlated with luteinizing hormone/follicle-stimulating hormone ratio (LH/
FSH) and SHBG. 
Conclusions: We demonstrated that women with PCOS are often vitamin D deficient. Its concentration was lower 
in patients with predominantly abdominal obesity as compared to subjects with gynoidal fat excess. In overweight/
obese subjects with PCOS, vitamin D correlated with fasting glucose and HOMA. The correlation with LH/FSH 
suggests that vitamin D status may contribute to hormonal dysregulation. Further studies are needed to elucidate 
a potentially different impact of abdominal and subcutaneous fat on vitamin D metabolism.
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Introduction
Vitamin	D	is	a	prohormone	produced	mainly	in	skin	through	
ultraviolet	 irradiation	 of	 7-dehydrocholesterol.	 After	 vitamin	
D	 is	metabolized	 to	25-hydroxyvitamin	D	and,	 in	 second	 step,	
to	 its	 active	 form	 -	 1α,25-dihydroxyvitamin	D,	 it	 acts	 through	
a	specific	nuclear	receptor	[1,	2].	Many	genes	encoding	proteins	
that	 regulate	 cell	 proliferation,	 differentiation,	 and	 apoptosis	
are	modulated,	at	least	in	part,	by	this	vitamin.	The	majority	of	
cells	 have	vitamin	D	 receptors,	 and	 some	convert	 25(OH)D	 to	
1α,25(OH)
2
D	[3].	
Vitamin	 D	 is	 thought	 to	 influence	 the	 development	 of	
PCOS	 through	 gene	 transcription	 and	 hormonal	 modulation	
that	influences	insulin	metabolism	and	fertility	regulation	[4,	5].	
Inverse	 associations	 between	 vitamin	D	 and	 indices	 of	 obesity	
in	women	with	PCOS	have	been	reported	[6-8].	In	several	trials,	
low	 levels	 of	 vitamin	 D	 in	 women	 with	 PCOS,	 with	 average	
25-hydroxyvitamin	D	levels	between	11	and	31	ng/ml	[6],	with	
the	majority	having	values	of	<20	ng/ml	(67–85%),	were	found	
[7,	8].	
Deficiency	 of	 this	 vitamin	 is	 associated	 with	 insulin	
resistance,	 signs	 of	 hyperandrogenemia,	 ovulatory	 and	
menstrual	 disturbances,	 lower	 pregnancy	 success,	 and	 elevated	
cardiovascular	 risk	 factors	 [7-10].	On	 the	other	hand,	 there	are	
also	evidences	for	beneficial	effects	of	vitamin	D	supplementation	
on	insulin	resistance	and	menstrual	dysfunction	in	women	with	
PCOS	[9,	11,	12].
In	our	study,	we	estimated	potential	associations	of	vitamin	
D	with	metabolic	 and	hormonal	 indices	 in	women	with	PCOS	
presenting	abdominal	and	gynoidal	type	of	obesity.
Material and methods
We	evaluated	26	overweight	and	obese	women,	aged	19-49	
years	(28.4	±	7.4),	with	BMI	of	26.8	-	53.8	kg/m2	(35.7	±	6.7).	All	
subjects	were	enrolled	from	the	population	of	out-patient	clinics	
of	gynecological	endocrinology	and	endocrinology	in	Żoliborz,	
Warsaw.	 PCOS	 was	 diagnosed	 on	 the	 basis	 of	 the	 Rotterdam	
consensus	 criteria	 [13].	 Other	 conditions:	 hyperprolactinemia,	
Cushing’s	syndrome,	non-classical	congenital	adrenal	hyperplasia	
were	 excluded.	 Also,	 current	 or	 previous	 (within	 the	 last	 3	
months)	 use	 of	 oral	 contraceptives	 and	 other	 hormonal	 drugs	
excluded	from	the	study.	
All	patients	were	classified	on	the	basis	of	measurements	of	
body	 composition	 to	 the	 group	with	 predominantly	 abdominal	
(group	I)	or	gynoidal	obesity	(group	II).
Subjects	were	 studied	after	 an	overnight	 fast.	Body	height	
and	weight	were	measured,	and	the	body	mass	index	(BMI)	was	
calculated.	Blood	was	collected	at	about	0800	h	for	vitamin	25(OH)
D,	 glucose,	 lipids,	 (total	 cholesterol,	 low-density	 lipoprotein	
cholesterol,	high-density	lipoprotein	cholesterol	and	triglycerides),	
leptin,	 insulin,	LH,	FSH,	 testosterone,	dehydroepiandrosterone-
sulfate	 (DHEA-S),	 17-hydroxyprogesterone	 and	 sex	 hormone-
binding	globulin	 (SHBG),	 through	 an	 iv	 catheter	 placed	 in	 the	
forearm.	Homeostasis	Model	of	Assessment	-	Insulin	Resistance	
(HOMA)	was	calculated	with	the	formula:	fasting	plasma	insulin	
(microinternational	units	per	milliliter)	x	fasting	plasma	glucose	
(millimoles	 per	 liter)	 /22.4.	 Free	 androgen	 index	 (FAI)	 was	
calculated	as	testosterone	(nmol/l)/SHBG	(nmol/l)	levels.	FAI		>5	
indicated	hyperandrogenemia.
All	 of	 the	 investigated	 subjects	 underwent	 transvaginal	
ultrasonography	 (TV-US)	 and	 US	 of	 the	 abdomen	 to	 exclude	
adrenal	pathology.	Body	composition	was	determined	by	dual-
energy	 absorptiometry	 (DEXA).	 The	 same	 two	 operators	
performed	all	TV-US	and	DEXA	measurements,	respectively.		
Levels	of	25(OH)D	were	interpreted	as	follows:	≥30	ng/mL:	
norm;	21-29	ng/mL:	insufficiency;	11-20	ng/mL:	deficiency;	≤10	
ng/ml:	deep	deficiency.		
The	 local	 ethics	 committee	 approved	 the	 study	 and	 an	
informed	consent	was	obtained	from	all	participants.
 Streszczenie
Cel pracy: Ocena potencjalnych zależności między stężeniem witaminy D a wskaźnikami metabolicznymi i hormo-
nalnymi u kobiet z zespołem policystycznych jajników (PCOS) i otyłością brzuszną lub gynoidalną. 
Materiał i metody: 26 kobiet (19-49 lat, BMI 26,8-53,8 kg/m2) z PCOS, z przewagą otyłości brzusznej lub gyno-
idalnej. Oceniono pomiary antropometryczne, skład ciała metodą DEXA, 25-hydroksywitaminę D, leptynę, glukozę, 
insulinę, wskaźnik insulinooporności HOMA, lipidy, androgeny i globulinę wiążącą hormony płciowe (SHBG) w su-
rowicy. 
Wyniki: U dwóch badanych stwierdzono obniżone stężenie, a u dwunastu niedobór lub głęboki niedobór witaminy 
D. Stężenie tej witaminy było niższe u otyłych w porównaniu do nieotyłych kobiet z PCOS, a także u badanych z do-
minacją otyłości brzusznej w porównaniu do pacjentek z przewagą otyłości gynoidalnej (9,60±3,7 vs 16,02±3,3 ng/
mL, p<0,04). U otyłych badanych stężenie witaminy D korelowało ze wszystkimi, z wyjątkiem tłuszczu gynoidalnego 
wskaźnikami otyłości, ze stężeniem glukozy i HOMA. Nie stwierdzono korelacji między witaminą D i androgenami. 
U badanych z dominacją otyłości brzusznej witamina D korelowała ze wskaźnikiem hormon luteinizujący/hormon 
stymulujący pęcherzyki (LH/FSH) i SHBG. 
Wnioski: U kobiet z PCOS niedobór witaminy D jest częsty. Stężenie tej witaminy jest niższe u pacjentek z przewa-
gą otyłości brzusznej w porównaniu do chorych z dominacją tłuszczu gynoidalnego i w obu grupach koreluje z BMI. 
U kobiet z nawagą/otyłością, stwierdzono korelację między witaminą D a glukozą na czczo i HOMA. Korelacja ze 
wskaźnikiem LH/FSH wskazuje na możliwy udział witaminy D w mechanizmie zaburzeń hormonalnych. Potrzebne 
są dalsze badania, które wyjaśnią wpływ tłuszczu brzusznego i gynoidalnego na metabolizm witaminy D.      
 Słowa kluczowe: witamina D / otyłość brzuszna / otyłość gynoidalna / 
                / zespół policystycznych jajników /
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Assays
Vitamin	 25(OH)D	 was	 measured	 by	 a	 chemiluminescent	
immunoassay	method	with	LIAISON®	analyzer	(DiaSorin,	Italy),	
with	 the	detection	 limit	of	<4.0	nmol/L	 (<10	nmol/l).	Glucose,	
cholesterol	and	triglycerides	were	measured	with	Cobas	integra	
400	plus	analyzer	(Roche	Diagnostics	Ltd,	Switzerland).	Insulin	
was	measured	by	an	immunoradiometric	method	(Insulin	IRMA	
–	Immunotech	SA,	France);	sensitivity	was	2.0	mIU/ml.	Leptin	
was	 measured	 by	 RIA	 (Linco	 Res.	 Inc,	 USA),	 using	 rabbit	
antibodies	against	human	leptin.	The	sensitivity	for	this	assay	was	
0.5	 ng/ml.	LH,	 FSH,	 estradiol,	DHEA-S	 and	 total	 testosterone	
were	 measured	 by	 immunechemiluminescence	 method	 with	
IMMULITE	 2000	 (Siemens	 Healthcare	 Diagnostics,	 Inc);	
sensitivity	 for	 LH,	 FSH,	 estradiol,	 DHEA-S	 and	 testosterone	
were:	0.1	mIU/ml,	0.05	mIU/ml,	15	pg/ml,	30	ng/ml	and	15	ng/
ml,	respectively.	The	results	of	testosterone	were	then	multiplied	
by	 factor	 3.46	 to	 obtain	 nmol/L.	 17-hydroxyprogesterone	 was	
measured	 by	 17OH-progesterone-RIA-CT	 Kit	 (DIAsource	
ImmunoAssays	SA,	Belgium),	with	the	detection	limit	of	0.02	ng/
ml.	SHBG	was	measured	by	IRMA	method	(Orion	Diagnostics	
Oy,	Finland),	detection	limit	1.3	nmol/l.	Urinary	17-ketosteroids	
were	measured	by	the	Zimmermann	method.
BMI	was	 calculated	 as	 the	 body	weight	 (kg)/height	 (m2).	
Measures	of	the	fat	mass	were	performed	by	the	method	in	which	
abdominal	fat	is	estimated	in	the	region	between	the	upper	part	
of	the	pelvis	with	the	upper	margin	96	mm	superior	to	the	lower	
part	of	this	region.	The	lateral	part	of	this	region	is	defined	by	the	
lateral	part	of	the	thorax.	The	upper	part	of	the	gynoid	fat	region	
is	defined	by	the	superior	part	of	trochanter	major,	with	the	lower	
margin	96	mm	inferior	to	the	upper	part	of	the	trochanter	major.	
The	lateral	part	of	this	region	is	defined	by	the	subcutaneous	tissue	
on	the	hip,	which	can	be	visualized	using	the	Image	Values	option	
[14,	15].	We	used	Lunar	Prodigy	(GE	Lunar,	Madison,	WI,	USA)	
equipment,	which	was	 calibrated	 each	day	with	 a	 standardized	
phantom	and	serviced	regularly.	The	coefficient	of	variation	for	
measurements	of	body	composition	with	this	method	is	about	2%.
Statistical analyses
All	data	are	presented	as	the	mean	±	SD.	The	distribution	of	
continuous	variables	was	tested	for	normality	by	the	Kolmogorov-
Smirnov	 test.	 Comparisons	 between	 groups	 with	 normal	
distribution	 of	 the	 data	 were	 performed	 by	 unpaired	 Student’s	
t-test.	Pearson	correlation	analysis	was	used	to	examine	bivariate	
relationships	between	data.	For	all	analyses,	a	two-tailed	P	≤	0.05	
was	considered	as	statistically	significant.	All	calculations	were	
performed	with	the	Statistica	8.0	software	package	(StatSoft	Inc,	
Tusla,	OK,	USA).
Results
Characteristics	 of	 patients	 with	 predominantly	 abdominal	
and	 gynoidal	 obesity	 are	 presented	 in	 Table	 1.	 Six	 patients	
(23.1%)	were	overweight,	 thirteen	were	obese	(50.0%)	and	 the	
remaining	 seven	 (26.9%)	 were	 considered	 as	 morbidly	 obese.	
Fourteen	 subjects	 (53.8%)	 were	 insulin	 resistant	 according	 to	
HOMA,	 ten	 from	group	 I	 and	 four	 from	group	 II.	All	 subjects	
were	 hyperandrogenic,	 although	 in	 five	 of	 them	 only	 clinical	
symptoms	of	hyperandrogenemia	were	found.		
Two	 patients	 from	 group	 II	 were	 vitamin	 D	 insufficient,	
whereas	deficiency	and	deep	deficiency	were	 found	 in	 ten	 (six	
from	group	 I	 and	 four	 from	group	 II)	 and	 two	 (from	group	 I),	
respectively.
Table	II	presents	correlations	between	vitamin	D	and	indices	
of	fatness.	In	all	of	our	patients	vitamin	D	correlated	negatively	
with	 all,	 except	 for	gynoid	 fat,	 indices	of	obesity.	Calculations	
performed	 separately	 for	 group	 I	 and	 II	 showed	 negative	
correlations	between	vitamin	D	and	BMI.	Figure	1	illustrates	the	
correlation	between	vitamin	D	and	abdominal	fat.	
An	 additional	 analysis	 revealed	 vitamin	 D	 levels	 to	 be	
significantly	 lower	 in	 women	 with	 higher	 abdominal	 fat	 mas	
(above	 medium)	 in	 comparison	 to	 patients	 with	 lower	 (below	
medium)	abdominal	fat:	9.6	±	3.7	ng/mL	vs.	16.40	±	3.7	ng/mL,	
respectively	 (p=0.01).	 On	 the	 other	 hand,	 patients	with	 higher	
vitamin	D	(above	medium)	in	comparison	to	women	with	lower	
levels	 of	 this	 vitamin	 (below	medium)	 had	 significantly	 lower	
abdominal	 fat	mass	and	BMI:	39.9	±	12.1%	vs.	52.0	±	12.1%,	
p<0.05,	 and	 30.3	 ±	 3.4	 kg/m2	 vs.	 37.4	 ±	 3.4	 kg/m2,	 p<0.02,	
respectively.
 
Figure 1. Negative correlation between serum 25-hydroxyvitamin D levels (ng/mL) 
and abdominal fat (%) in women with PCOS.  
ABF –  abdominal fat mass; ABF – masa tłuszczu brzusznego.
 
Figure 2. Negative correlation between serum 25-hydroxyvitamin D levels (ng/mL) 
and HOMA in overweight/obese women with PCOS.
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Correlations	of	25-hydroxyvitamin	D	with	serum	lipids	and	
glucose	metabolism	indices	are	presented	in	Table	3.	Significant	
negative	 correlations	 between	 vitamin	D	 and	 glucose	 levels	 as	
well	as	with	HOMA	index	(Figure	2)	were	found	in	all	patients.	
Also,	 serum	 insulin	 levels	 correlated	 nearly	 significantly	 with	
vitamin	D	(r=-0.49,	p=0.08)
Serum	 vitamin	 D	 levels	 correlated	 neither	 with	 serum	
testosterone	 and	 DHEA-S	 levels,	 nor	 with	 daily	 urine	
17-ketosteroids	 excretion,	 but	 correlated	 significantly	 with	 the	
LH/FSH	ratio	(r=0.68,	p=0.04).	This	correlation	persisted	when	
calculations	were	made	separately	for	patients	with	predominantly	
abdominal	type	of	obesity	(Table	IV).
Discussion
In	our	study,	we	attempted	to	investigate	potential	associations	
of	vitamin	D	with	metabolic	and	hormonal	indices	in	women	with	
PCOS,	presenting	abdominal	 and	gynoidal	 type	of	obesity.	We	
divided	the	overweight	and	obese	patients	on	the	basis	of	regional	
fat	mass	measures	into	groups	with	predominantly	abdominal	or	
gynoidal	types	of	obesity.	
Insufficiency	 in	 vitamin	D	was	 found	 in	 two	 subjects,	 ten	
patients	were	 vitamin	D-deficient,	 and	 in	 another	 two	 (26	 and	
41	years	old)	even	deep	deficiency	was	demonstrated.	Levels	of	
this	vitamin	were	lower	in	the	studied	overweight/obese	subjects	
as	compared	to	lean	women	with	PCOS	(unpublished	data),	and	
correlated	negatively	with	all,	except	for	gynoidal	fat,	measures	
of	obesity.	However,	only	correlations	with	BMI	persisted	when	
calculations	were	performed	separately	for	both	groups.	It	could	
be	speculated	that	small	sample	size	and	high	SD	contributed	to	
lack	of	statistical	significance	in	these	cases.	
Negative	associations	between	serum	vitamin	D	and	BMI,	
body	 fat	 and	waist	 circumference	 in	 women	with	 PCOS	 have	
been	 reported	 [8,	 16-18].	 This	 vitamin	 is	 fat	 soluble	 and	may	
be	 sequestered	 in	 adipose	 tissue	 with	 lower	 bioavailability,	 as	
a	 consequence	 [19].	 Another	 explanation	 might	 be	 less	 time	
spent	 outdoors	 by	 obese	 subjects,	 with	 subsequent	 insufficient	
biosynthesis	of	this	vitamin	in	the	skin.	Further,	we	demonstrated	
that	women	with	PCOS	with	predominantly	abdominal	 type	of	
obesity	have	significantly	lower	levels	of	vitamin	D	in	comparison	
to	subjects	with	predominantly	gynoidal	fat.	Additional	analysis	
showed	 that	 levels	 of	 this	 vitamin	 are	 significantly	 lower	
in	 women	 with	 higher	 abdominal	 fat	 mass	 (above	 medium)	
in	 comparison	 to	 patients	 with	 lower	 abdominal	 obesity.	 In	
previously	 published	 studies	 in	women	with	PCOS,	 vitamin	D	
levels	were	associated	with	higher	visceral	fat	surrounding	vital	
organs	 and	 with	 subcutaneous	 fat	 [20,	 21].	 However,	 regional	
fat	mass	has	not	been	taken	into	consideration	in	these	trials.	All	
these	findings	may	suggest	that	the	relationship	between	vitamin	
D	and	adiposity	may	not	be	as	simple	as	increased	sequestering	of	
this	vitamin	just	below	the	skin	surface.	In	fact,	they	may	indicate	
that	greater	amounts	of	visceral	relative	to	subcutaneous	fat	could	
have	an	impact	on	vitamin	D	levels.	Alternatively,	greater	relative	
amount	 of	 visceral	 fat	 and	decreased	vitamin	D	 levels	may	be	
markers	of	 the	 same	condition.	On	 the	other	hand,	The	Fourth	
Korea	National	Health	and	Nutrition	Examination	Survey	(IV-2)	
revealed	that	waist	circumference	was	not	significantly	associated	
with	vitamin	D.	Also,	a	significant	inverse	in	the	association	of	
this	vitamin	with	fasting	insulin	and	HOMA	in	both,	normal	and	
abdominally	obese,	groups	was	observed	[22].	We	found	negative	
correlations	 between	 vitamin	 D,	 serum	 fasting	 glucose	 levels	
and	HOMA.	However,	it	was	suggested	previously	that	obesity	
may	 have	 a	 confounding	 role	 in	 this	 relationship.	Multivariate	
regression	analysis	revealed	that	vitamin	D	level	was	a	significant	
and	 independent	 predictor	 for	 HOMA,	 along	 with	 BMI	 [17].	
Further	 studies	 will	 be	 needed	 to	 demonstrate	 conclusively	
whether	vitamin	D	levels	in	patients	with	PCOS	depend	on	the	
type	of	obesity,	and	to	elucidate	the	potentially	different	role	of	
abdominal	and	subcutaneous	fat	on	vitamin	D	metabolism.
Table I. Age, measures of fatness, metabolic parameters and hormonal results in 
patients with predominantly abdominal (n= 13, group I) and gynoidal (n=13, group II) 
obesity. 
Parameter
Group I
(n=13)
Group II
(n=13) P
Mean ± SD  Mean ± SD
Age (y) 30.2 ± 8.8  26.8 ± 6.2 NS
Body weight (kg) 104.1 ± 14.5 86.2 ± 16.6 <0.02
Body mass index 
(kg/m2)
36.6 ± 4.8 33.6 ± 6.5 NS
Fat mass (kg) 50.1 ± 9.1 37.7 ± 9.9 0.005
Fat mass of the 
trunk (kg)
26.7 ± 4.1 18.9 ± 3.9 <0.001
Abdominal fat 
mass (%)
53.7 ± 2.3  43.2 ± 6.2 0.0001
Gynoidal fat mass 
(%)
54.3 ± 1.6 50.5 ± 2.0 <0.001
TC (mmol/L) 4.98 ± 0.9 5.46 ± 1.2 NS
LDL (mmol/L) 3.05 ± 0.8 3.39 ± 1.0 NS
HDL (mmol/L) 1.18 ± 0.3 1.28 ± 0.2 NS
TG (mmol/L) 1.62 ± 0.5  1.69 ± 0.9 NS
Glucose (mmol/L) 5.35 ± 0.8 4.69 ± 0.5 <0.03
Insulin (µIU/mL) 16.91 ± 8.1 11.15 ± 8.9 0.1
HOMA 4.22 ± 2.5 2.36 ± 1.9 <0.05
Leptin (ng/mL) 48.31 ± 23.2 44.01 ± 30.6 NS
Testosterone 
(mmol/l)
2.63 ± 1.3 3.82 ± 2.1 NS
DHEA-S (ng/ml)
2288.0 ± 
1033.9
3032.0 ± 
994.7 NS
17-KS (µg/24 h) 16.1 ± 4.6 22.1 ± 11.6 NS
Free androgen 
index (FAI)
10.41 ± 9.4 17.57 ± 11.1 NS
LH/FSH 1.22 ± 0.7 1.29 ± 0.6 NS
SHBG (nmol/L) 35.5 ± 22.8 28.3 ± 16.2 NS
25-hydroxyvitamin 
D (ng/mL)
 9.60 ± 3.7 16.02 ± 3.3 <0.04
TC, total cholesterol; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; 
TG, triglycerides; HOMA, homeostatic model of assessment; DHEA-S, dehydroepiandrosterone-
sulfate; 17-KS, 17-ketosteroids; LH/FSH, luteinizing hormone/follicle-stimulating hormone ratio; 
SHBG, sex hormone-binding globulin; NS, not significant
TC, cholesterol całkowity; LDL, cholesterol o małej gęstości; HDL, cholesterol o dużej gęstości; TG, 
triglicerydy; HOMA, homeostatic model of assessment; DHEA-S, siarczan dehydroepiandrosteronu; 
17-KS, 17-ketosteroidy; LH/FSH, hormon luteinizujący/hormon stymulujący pęcherzyki; SHBG, 
globulina wiążąca hormony płciowe NS, brak znamienności statystycznej
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We	 did	 not	 find	 any	 correlations	 between	 vitamin	 D	 and	
androgens	 in	 our	 patients,	 neither	 in	 women	 with	 abdominal	
obesity	 nor	 in	 subjects	 with	 predominantly	 gynoidal	 fat.	
However,	 in	 women	 with	 predominantly	 abdominal	 obesity	
vitamin	D	correlated	with	LH/FSH	index	and	with	SHBG	levels.	
Significant	 correlation	 with	 LH/FSH	 suggests	 that	 vitamin	 D	
status	may	contribute	to	hormonal	dysregulation	in	women	with	
PCOS.	In	a	study	that	included	120	PCOS	patients,	an	association	
of	vitamin	 levels	with	 free	androgen	 index	and	SHBG,	but	not	
with	 total	 testosterone,	androstenedione,	DHEA-S,	estradiol,	or	
LH/FSH	ratio,	was	found	[8].	Our	results	are	consistent	with	data	
on	positive	associations	between	vitamin	D	and	SHBG	levels	[7,	
8,	17].	 It	has	been	suggested	 that	correlations	between	vitamin	
D	status	and	hyperandrogenism	may	be	due	to	the	reduction	in	
SHBG	that	results	from	obesity	[7,	8].
There	 are	 several	 limitations	 to	 our	 study.	 First	 of	 all,	
the	 sample	 size	 was	 relatively	 small	 and	 the	 results	 are	 often	
accompanied	 by	 high	 SD.	 In	 our	 opinion,	 this	 may	 be	 the	
main	 cause	 of	 lack	 of	 statistical	 significance	 in	 some	 cases.	
Secondly,	 it	 was	 impossible	 to	 classify	 patients	 to	 the	 group	
Table II. Correlations between serum 25-hydroxyvitamin D levels and indices of fatness in the studied women with PCOS. Pearson’s correlation coefficients r(X,Y) are shown.
Parameter
All patients
(n=26)
Group I
(n=13)
Group II
(n=13)
r (X,Y) r (X,Y) r (X,Y)
Body weight (kg) -0.93c -0.85 -0.99
Body mass index (kg/m2) -0.97c  -0.92a  -0.99a
Fat mass (g) -0.95c -0.84 -0.97
Fat mass of the trunk (g) -0.93c -0.79 -0.99
Abdominal fat mass (%) -0.84b -0.28 -0.99
Gynoidal fat mass (%) -0.37 0.83 -0.96
a – p< 0.05; b – p<0.01; c – p< 0.001
Table III. Correlations between serum 25-hydroxyvitamin D levels, serum lipids and indices of glucose metabolism in the studied women. Correlation coefficients r(X,Y) are 
shown.  
Parameter
All patients
(n=26)
Group I
(n=13)
Group II
(n=13)
r (X,Y) r (X,Y) r (X,Y)
TC (mmol/L) 0.08 -0.40 -0.21
LDL (mmol/L) 0.16 -0.42 -0.42
HDL (mmol/L) 0.21 0.65 0.33
TG (mmol/L) -0.46  -0.97b -0.19
Glucose (mmol/L) -0.67a -0.69 0.34
Insulin (µIU/mL) -0.49 -0.77 0.57
HOMA -0.56a -0.78 0.57
a – p<0.05; b – p<0.01; TC – total cholesterol; LDL – low density lipoprotein cholesterol; HDL – high density lipoprotein cholesterol; 
TG – triglycerides; HOMA – homeostatic model of assessment
Table IV. Correlations between serum 25-hydroxyvitamin D levels, serum androgens, 17-ketosteroids excretion, LH/FSH ratio and SHBG in overweight and obese women with 
a PCOS. Correlation coefficients r(X,Y) are shown.  
Variable
All patients
(n=26)
Group I
(n=13)
Group II
(n=13)
r (X,Y) r (X,Y) r (X,Y)
Testosterone (nmol/L) -0.01 -0.26  we-0.86
DHEA-S (ng/mL) -0.46 -0.67 -0.18
17-ketosteroids (µg/24 h) 0.17 0.08 -0.87
Free androgen index -0.10 -0.59 -0.44
LH/FSH  0.68a 0.98b -0.49
SHBG (nmol/L) 0.17 0.98a 1.00
a – p<0.05; b – p<0.01
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of	 purely	 abdominal	 or	 gynoidal	 obesity	 so	 patients	with	 only	
predominantly	abdominal	or	gynoidal	fat	excess	were	compared.	
Finally,	not	all	subjects	were	able	to	complete	all	the	tests,	what	
can	also	cause	errors.	
Conclusion
In	conclusion,	we	demonstrated	that	women	with	PCOS	are	
often	vitamin	D	deficient.	Levels	of	 this	vitamin	were	lower	in	
patients	with	predominantly	abdominal	obesity	in	comparison	to	
subjects	with	gynoidal	 fat	excess.	 In	overweight/obese	subjects	
with	 PCOS,	 vitamin	 D	 correlated	 with	 fasting	 glucose	 and	
HOMA	 index.	 Correlations	 of	 vitamin	 D	 with	 LH/FSH	 ratio	
and	SHBG	may	suggest	that	vitamin	D	status	may	contribute	to	
hormonal	dysregulation,	 at	 least	 in	patients	with	abdominal	 fat	
excess.	 Further	 studies	 are	 needed	 to	 elucidate	 the	 potentially	
different	 impact	of	abdominal	and	subcutaneous	fat	on	vitamin	
D	metabolism.
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